Advertisement FDA approves Orchid MDD drug - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves Orchid MDD drug

The US Food and Drug Administration has approved India-based Orchid Chemicals & Pharmaceuticals' abbreviated new drug application (ANDA) for Venlafaxine extended release (ER) capsules.

The drug has been given approval for its 37.5mg, 75mg and 150mg dosage strengths.

Venlafaxine ER capsules are indicated for the treatment of major depressive disorder (MDD) and social anxiety disorder.

Orchid has presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cadio vascular segment (CVS), nutraceuticals and other oral and sterile products.